159 related articles for article (PubMed ID: 35661562)
1. Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.
Knudsen MH; Lindberg U; Frederiksen JL; Vestergaard MB; Simonsen HJ; Varatharaj A; Galea I; Blinkenberg M; Sellebjerg F; Larsson HBW; Cramer SP
Mult Scler Relat Disord; 2022 Jul; 63():103891. PubMed ID: 35661562
[TBL] [Abstract][Full Text] [Related]
2. Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
Cramer SP; Simonsen HJ; Varatharaj A; Galea I; Frederiksen JL; Larsson HBW
Ann Neurol; 2018 May; 83(5):902-914. PubMed ID: 29604233
[TBL] [Abstract][Full Text] [Related]
3. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
[TBL] [Abstract][Full Text] [Related]
4. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
[TBL] [Abstract][Full Text] [Related]
5. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis.
Lund H; Krakauer M; Skimminge A; Sellebjerg F; Garde E; Siebner HR; Paulson OB; Hesse D; Hanson LG
PLoS One; 2013; 8(2):e56375. PubMed ID: 23441184
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study.
Brecl Jakob G; Barun B; Gomezelj S; Gabelić T; Šega Jazbec S; Adamec I; Horvat Ledinek A; Rot U; Krbot Skorić M; Habek M
Neurol Sci; 2021 Nov; 42(11):4591-4597. PubMed ID: 33660157
[TBL] [Abstract][Full Text] [Related]
9. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
10. Abnormal blood-brain barrier water exchange in chronic multiple sclerosis lesions: A preliminary study.
Wengler K; Ha J; Syritsyna O; Bangiyev L; Coyle PK; Duong TQ; Schweitzer ME; He X
Magn Reson Imaging; 2020 Jul; 70():126-133. PubMed ID: 32353529
[TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier permeability measured using dynamic contrast-enhanced magnetic resonance imaging: a validation study.
Varatharaj A; Liljeroth M; Darekar A; Larsson HBW; Galea I; Cramer SP
J Physiol; 2019 Feb; 597(3):699-709. PubMed ID: 30417928
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
15. Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.
Eftekhari E; Hojjat SP; Vitorino R; Carroll TJ; Cantrell CG; Lee L; Taylor MW; Morrow SA; Benhabib H; Aviv RI; Kassner A
Neuroradiology; 2017 Aug; 59(8):771-780. PubMed ID: 28623483
[TBL] [Abstract][Full Text] [Related]
16. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
17. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
Vavasour IM; Tam R; Li DK; Laule C; Taylor C; Kolind SH; MacKay AL; Javed A; Traboulsee A
Mult Scler; 2019 May; 25(6):811-818. PubMed ID: 29663845
[TBL] [Abstract][Full Text] [Related]
18. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
Manso J; Zhu YH; Margoni M; Rinaldi F; Censi S; Carducci S; Cosma C; Plebani M; Gallo P; Mian C
Clin Endocrinol (Oxf); 2022 Sep; 97(3):331-338. PubMed ID: 34724236
[TBL] [Abstract][Full Text] [Related]
20. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
